Coagulopathies after vaccination against SARS-CoV-2: The sole solution might lead to another problem DOI Creative Commons
Saeed Hassani,

Meshkat Mesh Poortavakol,

Mohammad Sayyadi

и другие.

Iranian Journal of Blood and Cancer, Год журнала: 2022, Номер 14(4), С. 125 - 139

Опубликована: Дек. 1, 2022

thrombotic thrombocytopenia (VITT) Covid-19 vaccination Platelet factor 4(PF-4)The common reported adverse impacts of COVID-19 include the injection site's local reaction followed by various non-specific flu-like symptoms.Nevertheless, uncommon cases vaccine-induced immune and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (ChAdOx1 nCoV-19 vaccine, Ad26.COV2 vaccine) have been reported.This literature review was performed using PubMed Google Scholar databases appropriate keywords their combinations: SARS-CoV-2, adenovirus, spike protein, thrombosis, thrombocytopenia, (VITT), NF-kappaB, adenoviral vector, platelet 4 (PF4), Vaccine, AstraZeneca COVID ChAdOx1 AZD1222 coagulopathy.The abstracts titles each article were assessed authors for screening inclusion English reports about post-vaccine CVST VITT in humans also collected.Some SARS-CoV-2 based on mRNA, or inactivated virus accepted are being pragmatic global.Nevertheless, recent augmented statistics normally very infrequent types associated with stated, predominantly context vaccine from Astra Zeneca.The numerical prevalence these side effects seems to associate this particular type, i.e., vector-based vaccines, but meticulous molecular mechanisms still not clear.The present summarizes latest data hypotheses cellular into one integrated hypothesis demonstrating that coagulopathies, including thromboses, other effects, correlated an interaction two components vaccine.

Язык: Английский

Coagulopathies after vaccination against SARS-CoV-2: The sole solution might lead to another problem DOI Creative Commons
Saeed Hassani,

Meshkat Mesh Poortavakol,

Mohammad Sayyadi

и другие.

Iranian Journal of Blood and Cancer, Год журнала: 2022, Номер 14(4), С. 125 - 139

Опубликована: Дек. 1, 2022

thrombotic thrombocytopenia (VITT) Covid-19 vaccination Platelet factor 4(PF-4)The common reported adverse impacts of COVID-19 include the injection site's local reaction followed by various non-specific flu-like symptoms.Nevertheless, uncommon cases vaccine-induced immune and cerebral venous sinus thrombosis (CVST) following viral vector vaccines (ChAdOx1 nCoV-19 vaccine, Ad26.COV2 vaccine) have been reported.This literature review was performed using PubMed Google Scholar databases appropriate keywords their combinations: SARS-CoV-2, adenovirus, spike protein, thrombosis, thrombocytopenia, (VITT), NF-kappaB, adenoviral vector, platelet 4 (PF4), Vaccine, AstraZeneca COVID ChAdOx1 AZD1222 coagulopathy.The abstracts titles each article were assessed authors for screening inclusion English reports about post-vaccine CVST VITT in humans also collected.Some SARS-CoV-2 based on mRNA, or inactivated virus accepted are being pragmatic global.Nevertheless, recent augmented statistics normally very infrequent types associated with stated, predominantly context vaccine from Astra Zeneca.The numerical prevalence these side effects seems to associate this particular type, i.e., vector-based vaccines, but meticulous molecular mechanisms still not clear.The present summarizes latest data hypotheses cellular into one integrated hypothesis demonstrating that coagulopathies, including thromboses, other effects, correlated an interaction two components vaccine.

Язык: Английский

Процитировано

0